The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Integrating ctDNA in clinical decision-making for colorectal cancer
Emerik Osterlund, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the use of circulating tumor DNA (ctDNA) in routine colorectal cancer management in the United States, where it is reimbursed and commonly used to monitor patients after surgery. This policy allows for potential de-intensification of treatment to avoid unnecessary chemotherapy and side effects, and ctDNA can minimize unnecessary treatments and their associated side effects. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in the United States where this was conducted, ctDNA is a part of routine healthcare and is reimbursed as well. So it’s quite common that patients are followed with ctDNA after surgeries and in some instances you might choose to de-intensify the treatment in order to not give unnecessary chemotherapy and unnecessary side effects to the patients.
This transcript is AI-generated...
So in the United States where this was conducted, ctDNA is a part of routine healthcare and is reimbursed as well. So it’s quite common that patients are followed with ctDNA after surgeries and in some instances you might choose to de-intensify the treatment in order to not give unnecessary chemotherapy and unnecessary side effects to the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
